logo
#

Latest news with #AccreditedInvestors

Bona Vita Properties Launches Global Luxury Vacation Investment Platform
Bona Vita Properties Launches Global Luxury Vacation Investment Platform

Yahoo

time10-07-2025

  • Business
  • Yahoo

Bona Vita Properties Launches Global Luxury Vacation Investment Platform

New Model Gives Investors Access to International Luxury Vacation Rentals with Passive Income Potential MIAMI, July 10, 2025 /PRNewswire/ -- Bona Vita Properties, a luxury global vacation rental investment platform, has launched a new offering that provides accredited investors with access to passive income opportunities through co-ownership of fully managed vacation villas. Eliminating the complexity of traditional ownership, the platform simplifies access to the growing luxury short-term rental market. The global vacation rental market is projected to reach $119 billion by 2030. Bookings over $1,000 per night have risen 73% since 2019, signaling growing demand for premium accommodations. Bona Vita allows investors to tap into this trend through a white glove investment experience in luxury rentals. Bona Vita targets emerging luxury enclaves in the Caribbean, South America, and Southern Europe—regions with trends of strong tourism, limited upscale supply, and premium nightly rates. Villas are designed to deliver exceptional guest experiences and strong income potential through careful selection, staging, and five-star staffing. From acquisition to hospitality, Bona Vita handles every detail to eliminate the operational burden for investors. Benefits include: Passive Ownership – No management required; Bona Vita oversees operations Quarterly Distributions* – Income from rental cash flow and hospitality services Luxury Hospitality – Premium services designed to enhance guest satisfaction and returns Local Expertise – In-market partners support sourcing and execution Global Diversification – Access to premier villas in top international destinations To learn more or request access to current offerings, visit: Disclaimer: This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities, which can only be made by receipt of a private placement memorandum relating to a proposed investment opportunity. Investing in private placements involves a high degree of risk, including the risk of loss of your entire investment. Prospective investors should consult their own legal, tax, and financial advisors prior to making any investment decision. *Quarterly distributions are not guaranteed. About Bona Vita PropertiesBona Vita Properties is a luxury real estate investment platform offering accredited investors fractional ownership in a curated portfolio of international vacation villas. Backed by decades of experience in real estate, hospitality and property management, Bona Vita delivers a fully managed, income-generating investment experience complete with high-end amenities, professional operations and five-star guest services. For more information, visit: Contact:Jessica DeMarinojdemarino@ View original content to download multimedia: SOURCE Bona Vita Properties Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BMO Launches Alpha Managers Hedge Fund, in Collaboration with Goldman Sachs Asset Management
BMO Launches Alpha Managers Hedge Fund, in Collaboration with Goldman Sachs Asset Management

Globe and Mail

time10-06-2025

  • Business
  • Globe and Mail

BMO Launches Alpha Managers Hedge Fund, in Collaboration with Goldman Sachs Asset Management

/NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OR TO U.S. PERSONS/ TORONTO, June 10, 2025 /CNW/ - BMO Global Asset Management ('BMO GAM') today announced the launch of its new Alpha Managers Hedge Fund ('Fund'), complementing BMO GAM's innovative suite of alternative investment strategies for accredited investors. The new fund combines high-conviction strategies from global hedge fund managers and aims to deliver alpha, low volatility and less correlated returns to traditional asset classes.

MedX Announces Final Closing of Non-Brokered Private Placement
MedX Announces Final Closing of Non-Brokered Private Placement

National Post

time09-06-2025

  • Business
  • National Post

MedX Announces Final Closing of Non-Brokered Private Placement

Article content MISSISSAUGA, Ontario — MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ('Unit'). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant (s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (' MI 61-101 '). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met. Article content Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants (' Agent's Warrant(s) ') (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Article content Article content Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. Article content About MedX Health Corp.: Article content MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit Article content This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Article content Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store